Bicara Therapeutics BCAX Share-Based Payment Award Options Outstanding - Number
Share-Based Payment Award Options Outstanding - Number at other companies
Other financials
Where this comes from
Reported directly by Bicara Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.
The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bicara Therapeutics's share-based payment award options outstanding - number.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bicara Therapeutics's share-based payment award options outstanding - number?
- Bicara Therapeutics (BCAX) reported share-based payment award options outstanding - number of 11.9M in Q1 2026.
- How has Bicara Therapeutics's share-based payment award options outstanding - number changed year-over-year?
- Bicara Therapeutics's share-based payment award options outstanding - number increased by 43.6% year-over-year, from 8.3M to 11.9M.
- What is the long-term trend for Bicara Therapeutics's share-based payment award options outstanding - number?
- Over 2 years (2023 to 2025), Bicara Therapeutics's share-based payment award options outstanding - number has grown at a 42.5% compound annual growth rate (CAGR), from 4.9M to 9.9M.
- What does share-based payment award options outstanding - number mean?
- This is the total count of stock options granted to employees and directors that remain unexercised at the reporting date. It reflects the total volume of potential equity claims currently held by the workforce. This metric is a key component in calculating fully diluted share counts.